
    
      PRIMARY OBJECTIVES:

      I. To investigate whether adding the PDE5 inhibitor, tadalafil, to nivolumab therapy affects
      intratumoral and systemic anti-tumor immunity.

      SECONDARY OBJECTIVES:

      I. Characterize the combined effects of nivolumab and tadalafil on safety, exosome
      composition and function, the composition of intratumoral immune cell populations, wound
      healing, and tumor radiographic response.
    
  